nference Revenue and Competitors
Estimated Revenue & Valuation
- nference's estimated annual revenue is currently $178.1M per year.
- nference's estimated revenue per employee is $295,400
- nference's total funding is $145M.
- nference has 603 Employees.
- nference grew their employee count by 20% last year.
nference Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is nference?
Powered by its artificial intelligence software platform, nferX, nference's mission is to synthesize the exponentially growing biomedical knowledge. nferX uses state-of-the-art neural networks (shallow and deep learning models) for real-time, automated extraction of knowledge from the commercial, scientific and regulatory body of literature. The platform enables a diverse set of applications ranging from R&D to commercial strategy and operations in the life sciences ecosystem. The long-term goal of the nferX platform is to become the connecting fabric of the various silos of information that exist across health care. Founded by Murali Aravamudan and Venky Soundararajan, Ph.D., nference is led by a multidisciplinary team of serial entrepreneurs from the tech and biotech worlds and PhDs in Biology/Genomics from MIT and Harvard Medical School. The investors in nference are Matrix Partners and Matrix Capital Management.keywords:Biotechnology, Natural Language Processing, Artificial Intelligence / Machine Learning
Number of Employees
Employee Growth %
D., from nference in Cambridge, Massachusetts, and colleagues evaluated the safety of third-dose vaccination with U.S. Food and Drug...
nference uses transformer AI models to employ self-supervised learning from large volumes of unstructured data without labels,...
nference uses transformer AI models to employ self-supervised learning from large volumes of unstructured data without labels, translating vast...
CAMBRIDGE, Mass., March 23, 2021 /PRNewswire/ -- nference, the AI-driven health technology company, today announced publication in EClinicalMedicine of study "Pre-existing conditions are associated with COVID patients hospitalization, despite confirmed clearance of SARS-CoV-2 virus" that sheds ...
CAMBRIDGE, Mass., March 10, 2021 /PRNewswire/ -- nference, the AI-driven health technology company, today announced publication in EClinicalMedicine of "Enoxaparin is associated with lower rates of thrombosis, kidney injury, and mortality than Unfractionated Heparin in hospitalized COVID patie ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|